Chemomab Therapeutics (CMMB) Operating Leases (2019 - 2025)

Chemomab Therapeutics (CMMB) has reported Operating Leases for 7 consecutive years, with $179000.0 the latest figure, recorded in Q1 2025.

• For the quarter ending Q1 2025, Operating Leases fell 36.07% year-over-year to $179000.0; the trailing twelve-month figure through Mar 2025 stood at $179000.0 (down 36.07% YoY), and the FY2024 full-year result was $209000.0, down 46.68% from the prior year.
• Operating Leases fell to $179000.0 in Q1 2025 per CMMB's latest filing, from $209000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $392000.0 in Q4 2023 and bottomed at $5000.0 in Q3 2023.
• Historically, Operating Leases has averaged $205294.1 across 5 years, with a median of $209000.0 in 2024.
• The sharpest annual moves came in 2023 and 2024: Operating Leases tumbled 95.76% in 2023, then surged 4500.0% in 2024.
• Over 5 years, Operating Leases stood at $343000.0 in 2021, then sank by 73.47% to $91000.0 in 2022, then surged by 330.77% to $392000.0 in 2023, then tumbled by 46.68% to $209000.0 in 2024, then dropped by 14.35% to $179000.0 in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $179000.0, $209000.0, and $230000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.